Despite recent advances in the treatment of type 1 diabetes due to the introduction of new fast-acting and basal insulin analogs, insulin pumps and the possibility of continuous glucose monitoring (CGM) the majority of type 1 diabetic patients do not achieve and maintain adequate glycosylated hemoglobin levels [81]. This evidence concerns the gene INS and type 1 diabetes mellitus.